Patents by Inventor Philip Perera

Philip Perera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260174777
    Abstract: Provided is a method of treatment of a 5-hydroxytryptamine (HT)2C receptor-associated disorder comprising: prescribing and/or administering to an individual in need thereof, (R)-N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
    Type: Application
    Filed: February 17, 2026
    Publication date: June 25, 2026
    Inventors: Dolly PARASRAMPURIA, Chadwick J. OREVILLO, Philip PERERA
  • Publication number: 20250170142
    Abstract: Provided is a method of treatment of a 5-hydroxytryptamine (HT)2C receptor-associated disorder comprising: prescribing and/or administering to an individual in need thereof, (R)-N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
    Type: Application
    Filed: July 8, 2024
    Publication date: May 29, 2025
    Inventors: Dolly PARASRAMPURIA, Chadwick J. OREVILLO, Philip PERERA
  • Publication number: 20230293546
    Abstract: Provided is a method of treatment of a 5-hydroxytryptamine (HT)2C receptor-associated disorder comprising: prescribing and/or administering to an individual in need thereof, (R)-N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
    Type: Application
    Filed: March 9, 2023
    Publication date: September 21, 2023
    Inventors: Dolly PARASRAMPURIA, Chadwick J. OREVILLO, Philip PERERA
  • Publication number: 20170273968
    Abstract: Methods of rehabilitation of neurological disorders, including neurological deficits associated with neurotraumas, such as stroke and traumatic brain injury, and with muscle disorders, that includes administering to a subject a MAO-B inhibitor.
    Type: Application
    Filed: September 17, 2015
    Publication date: September 28, 2017
    Inventors: Timothy Tully, Philip Perera